MedWatch

Bionor Chairman: Solomon left of his own volition

David Solomon was not fired from his position as CEO of Norwegian biotech company Bionor Pharma; he and the Board chose to part ways as they did not see eye to eye on the company’s strategy due to failed fundraising efforts in the US, according to the Chairman of the Board.

Former Zealand Pharma CEO David Solomon is history in the Norwegian company Bionor Pharma, which he joined as chief executive just 15 months ago. But his departure was not forced and the CEO left of his own volition, says Bionor’s Chairman, Per Thoresen.

“When the Board posed questions about the future strategy in terms of fundraising and the setup of the company, David Solomon wished to resign,” Per Thoresen says in a phone interview with MedWatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier